問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張崇信

Recruiting

List

40Cases

2022-06-13 - 2025-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-12-01 - 2029-04-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-30 - 2028-11-27

Phase II

Active
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    MEDI5752 AVASTIN LENVIMA AZD2936

Participate Sites
8Sites

Recruiting8Sites

2018-01-01 - 2023-05-12

Phase II/III

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Risankizumab

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2017-12-21 - 2020-04-01

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Risankizumab(ABBV-066)

Participate Sites
6Sites

Recruiting5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2024-01-01 - 2030-11-30

Phase II/III

Active
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment –LIVIGNO-2

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Livmoniplimab (ABBV-151)；Budigalimab (ABBV-181)

Participate Sites
5Sites

Recruiting5Sites

2018-01-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-02-01 - 2023-09-21

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-09-23 - 2028-02-13

Phase II

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic hepatitis B virus (HBV) infection

  • Test Drug

    Film-coated tablet Film-coated tablet

Participate Sites
8Sites

Recruiting8Sites

2023-10-01 - 2026-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB